X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New study shows why insurers should share rebates with Medicare Part D beneficiaries on a mandatory basis

By Holly Campbell  |    February 14, 2019
New research by three Milliman actuaries explores the dynamics underlying the relationship between Medicare Part D plan premiums and sharing rebates directly with beneficiaries at the pharmacy...   Read More

New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions

By Holly Campbell  |    January 18, 2019
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) potential budget impact analyses are not...   Read More

10 things you should know about medicine spending and costs

By Holly Campbell  |    January 2, 2019
Discussions about costs are important. Too often patients struggle to afford the medicines they need. Our industry is committed to working with policymakers on solutions that enhance the...   Read More

Six key facts about the market for insulins

By Holly Campbell  |    December 17, 2018
The insulin market is commonly mischaracterized as lacking competition. In fact, robust competition among biopharmaceutical companies that produce insulin results in increasing levels of discounts...   Read More

What they are saying: PhRMA member executives on industry’s new approach to DTC television advertising

By Holly Campbell  |    October 15, 2018
Pharmaceutical Research and Manufacturers of America (PhRMA) member companies today announced their commitment to providing more transparency about medicine costs to help patients make more...   Read More

Americans want to know more than just the list price of a medicine—and we’re answering their call

By Robert Zirkelbach  |    October 15, 2018
The biopharmaceutical industry is answering the call to provide more information about medicine costs. As innovators of life-saving therapies, we recognize the importance of giving people the...   Read More

Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles

By Katie Koziara  |    October 4, 2018
According to a new report by IQVIA Institute for Human Data Science, more and more patients are asked to pay high cost sharing due to changes in benefit design. Previous analysis has shown that...   Read More

Experts agree: the Bipartisan Budget Act changes to Medicare Part D jeopardize the program

By Juliet Johnson  |    September 24, 2018
The changes made to Part D in the Bipartisan Budget Act (BBA) that passed in February threaten the program’s successful competitive structure. While these changes closed the donut hole a year...   Read More

What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?

By Juliet Johnson  |    September 13, 2018
Right now, Congress has the opportunity to make two small fixes that will protect seniors in the Medicare Part D donut hole and save them money on out-of-pocket costs for their medicines.  These...   Read More

Number of value-based contracts continues to rise

By Michelle Drozd  |    August 27, 2018
The list of publicly announced value-based contracts (VBCs) – also called results-based contracts – between biopharmaceutical companies and health plans continued to grow over the last quarter –...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates